Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanomaterials
Volume 2015 (2015), Article ID 471283, 10 pages
Research Article

Preparation and Evaluation of PEGylated and Folate-PEGylated Liposomes Containing Paclitaxel for Lymphatic Delivery

1College of Pharmacy, CHA University, Seongnam-si 463-712, Republic of Korea
2Department of Medical Management, Chodang University, Muan 534-701, Republic of Korea
3College of Pharmacy, Chonnam National University, Gwangju 500-757, Republic of Korea

Received 19 September 2014; Accepted 24 November 2014

Academic Editor: Sabine Szunerits

Copyright © 2015 Hea-Young Cho et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This study attempted to prepare polyethylene-glycol modified (PEGylated) and folate-PEGylated liposomes containing paclitaxel (Ptx) in order to reduce the toxicity and improve the bioavailability and biocompatibility by targeting drugs to the lymphatics using cancer cell specific ligand folate to prevent metastasis via the lymphatic system. Liposomes were prepared by lipid film hydration method using PEG and folate-PEG as surface modifiers. The mean particle size and encapsulation efficiency of liposomes were  nm and % for PEGylated liposome and  nm and % for folate-PEGylated liposome, respectively. According to stability test, it could be confirmed that PEGylated and folate-PEGylated liposomes were stable for at least 5 days. After intravenous administration of the PEGylated and folate-PEGylated liposomes to rats, the (total clearance) and (half-life) were significantly different () compared with those of PADEXOL Inj. In targeting efficiency, calculated as the concentration ratio of Ptx in lymph nodes and plasma, there was significant increase in targeting efficiency at lymph nodes (). From these results, we could conclude that the prepared Ptx-containing PEGylated and folate-PEGylated liposomes are good candidates for the targeted delivery of the drug to lymphatic system.